TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) — TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced today that with the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), the Company regained compliance with Nasdaq listing rules and posted net income of over $21 million for […]
Category Archives: Pr Newswire
BEIJING, June 27, 2024 /PRNewswire/ — Cheche Group Inc. (NASDAQ: CCG) (“Cheche” or the “Company”), China’s leading auto insurance technology platform, today announced that it has entered into a strategic partnership with Beijing Anpeng Insurance Broker Co., Ltd. (“Beijing Anpeng”), as Cheche continues to deepen its collaborations with new energy vehicle (“NEV”) manufacturers in China. […]
Embracing the Power of the Skin Microbiome with BIOJUVE JOHNSON CITY, Tenn., June 27, 2024 /PRNewswire/ — Microbiome research has revolutionized our understanding of human health, highlighting the vital role our body’s microbiome plays in maintaining overall well-being. In honor of World Microbiome Day, Crown Laboratories, Inc. (“Crown”) and BIOJUVE® reaffirm their dedication to pioneering […]
Strategic plans for a diverse supplier network and enhanced trade opportunities unveiled GENEVA, June 27, 2024 /PRNewswire/ — Alibaba.com, a leading platform for global business-to-business (B2B) e-commerce and a unit of Alibaba International Digital Commerce Group, today honored businesses in their pursuit of success and global growth ahead of Micro-, Small and Medium-Sized Enterprise (MSME) […]
The 160 MW North Fork Solar Project is now in operation, supplying power to the Oklahoma Municipal Power Authority GUELPH, ON, June 27, 2024 /PRNewswire/ — Recurrent Energy, a subsidiary of Canadian Solar Inc. (“Canadian Solar”) (NASDAQ: CSIQ) and a global developer, owner, and operator of solar and energy storage assets, announced today that it […]
Latest funding round capitalizes on recent growth, catalyzing further product innovation and expansion into new markets SAN FRANCISCO, June 27, 2024 /PRNewswire/ — Odaseva, the leading enterprise data security platform for Salesforce, today announced a $54 million Series C equity financing, bringing the total company funding to more than $90 million. Silver Lake Waterman led […]
Pr Newswire
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
27
Jun
Jun
Tokyo, Japan and Cambridge, UK, 27 June 2024 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to […]
Pr Newswire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
27
Jun
Jun
Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL EPKINLY offers an off-the-shelf, T-cell engaging treatment option that enables treatment across practice settings to address high clinical need EPKINLY is the first and only bispecific antibody approved in the […]
27
Jun
Jun
Philadelphia Magazine names Cross Medical Group’s founder as one of the city’s top doctors for 2024 PHILADELPHIA, June 26, 2024 (GLOBE NEWSWIRE) — Each year, Philadelphia Magazine publishes an issue celebrating the top doctors in the city, and Cross Medical Group founder Dr. Kevin J. Cross, a world-renowned plastic surgeon based in Villanova and Philadelphia, […]
Pr Newswire
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
27
Jun
Jun
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the US for this […]